Effects of Etanercept on Clinical and Immunological outcomes in Iraqi Patients with Rheumatoid Arthritis

Authors

  • Qateralnada Rifaat Altohmoschi
  • Mohammed AH Jabarah AL-Zobaidy
  • Nizar Abdulateef Jasim

DOI:

https://doi.org/10.37506/ijfmt.v15i4.17032

Keywords:

Etanercept, Immunological markers. Methotrexate, Pharmacology, Rheumatoid arthritis, SDAI

Abstract

Background: Rheumatoid Arthritis is a chronic autoimmune disease affects joints and connective tissues
where different types of cytokines are involved in its pathogenesis and progression. Biological drugs are
considered to be a more targeted treatments for rheumatoid arthritis. Therefore, the aim of current study
was to explore the effects of etanercept, a biological drug that inhibits tumor necrosis-alpha, on clinical and
immunological variables in Iraqi patients with RA. Methods: A prospective open-label study conducted
from February to November/ 2020 at Rheumatology Unit, Baghdad Teaching Hospital/ Medical city, Iraq.
The study involved 75 patients with rheumatoid arthritis who underwent a 12-week course of treatment with
etanercept monotherapy or combined with methotrexate. Assessments of disease activity and immunological
markers (using SDAI and ELISA technique, respectively) were performed for the patients after the course of
treatment and compared with healthy controls. Results: Data from current study showed that disease activity
was not affected by type of treatment and immunological markers were higher in patients with rheumatoid
arthritis than in control subjects regardless of type of treatment. Conclusion: To achieve an effective
control of rheumatoid arthritis disease activity, treatment with etanercept (monotherapy or combined with
methotrexate) needs to be continued for more 12 weeks.

Author Biographies

Qateralnada Rifaat Altohmoschi

M.Sc. Student, of Pharmacology Department of Pharmacology, College of Medicine/ University of Baghdad, Iraq

Mohammed AH Jabarah AL-Zobaidy

Assistant Professor of Pharmacology, Department of Pharmacology, University of Baghdad, Iraq

Nizar Abdulateef Jasim

Professor of Rheumatology,Department of Medicine, College of Medicine/ University of Baghdad, Iraq

Published

2021-08-16

How to Cite

Qateralnada Rifaat Altohmoschi, Mohammed AH Jabarah AL-Zobaidy, & Nizar Abdulateef Jasim. (2021). Effects of Etanercept on Clinical and Immunological outcomes in Iraqi Patients with Rheumatoid Arthritis. Indian Journal of Forensic Medicine & Toxicology, 15(4), 2189-2197. https://doi.org/10.37506/ijfmt.v15i4.17032